U.S. stock indexes struggled for direction on Wednesday after a strong start to the week, as investors digested a fresh update on Pfizer and BioNTech’s COVID-19 vaccine, while the fast-spreading Omicron variant kept bigger bets in check.
Pfizer and BioNTech said their three-shot course of COVID-19 vaccine was able to neutralize the new Omicron variant in a laboratory test and they could deliver an upgraded vaccine in March 2022 if needed.
